Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 127405
Published online Nov 24, 2026. doi: 10.5306/wjco.127405
Published online Nov 24, 2026. doi: 10.5306/wjco.127405
Table 1 Representative screening and diagnostic metrics of sarcopenia
| Metrics | Summary | Methodology | Asian/AWGS | Western/EWGSOP | ||
| Cut-off for men | Cut-off for women | Cut-off for men | Cut-off for women | |||
| Calf circumference | Thickest circumference | Tape measure | < 34 cm | < 33 cm | < 34 cm1 | < 33 cm1 |
| SMI | Total skeletal muscle area at L3 divided by squared height | CT | ≤ -2 SD of young adults | ≤ -2 SD of young adults | ≤ -2 SD of young adults | ≤ -2 SD of young adults |
| PMI | Total psoas muscle area at L3 divided by squared height | CT | ≤ -2 SD of young adults | ≤ -2 SD of young adults | ≤ -2 SD of young adults | ≤ -2 SD of young adults |
| ASMI | Appendicular muscle mass divided by squared height | DXA | < 7.0 kg/m2 (> 65 years) | < 5.4 kg/m2 (> 65 years) | < 7.0 kg/m2 | < 5.5 kg/m2 |
| < 7.2 kg/m2 (for 50-64 years) | < 5.5 kg/m2 (for 50-64 years) | |||||
| ASMI | Appendicular muscle mass divided by squared height | BIA | < 7.0 kg/m2 (for > 65 years) | < 5.7 kg/m2 (for > 50 years) | < 8.50 kg/m2 for severe | < 5.75 kg/m2 for severe |
| < 7.6 kg/m2 (for 50-64 years) | < 10.75 kg/m2 for moderate | < 6.75 kg/m2 for moderate | ||||
| SARC-F | 5 items (muscle strength, assistance with walking, rise from a chair, climb stairs, and falls) | Questionnaire | ≥ 4 points | ≥ 4 points | ≥ 4 points | ≥ 4 points |
| SARC-CalF | SARC-F + calf circumference | Questionnaire, tape measure | ≥ 11 points | ≥ 11 points | ≥ 11 points1 | ≥ 11 points1 |
| Hand grip | Maximum strength in 2-3 trials | Hand dynamometer | < 28 kg (for > 65 years) | < 18 kg (> 65 years) | < 27 kg | < 16 kg |
| < 34 kg (for 50-64 years) | < 20 kg (for 50-64 years) | |||||
| Repeated chair stand test | Total time of 5 rises | ≥ 12 seconds (for > 65 years) | ≥ 12 seconds (for > 65 years) | ≥ 15 seconds | ≥ 15 seconds | |
| ≥ 10 seconds (for 50-64 years) | ≥ 10 seconds (for 50-64 years) | |||||
| Gait speed | Speed in a 4- or 6-m walk | < 1.0 m/second (for > 65 years) | < 1.0 m/second (for > 65 years) | < 0.8 m/second | < 0.8 m/second | |
| < 1.2 m/second (for 50-64 years) | < 1.2 m/second (for 50-64 years) | |||||
| SPPB | Standing balance, gait speed, and chair-stand ability | ≤ 9 points (full score: 12) | ≤ 9 points (full score: 12) | ≤ 8 points (full score: 12) | ≤ 8 points (full score: 12) | |
Table 2 Summary of the safety and efficacy of treatments for colorectal cancer according to the three sex, seniors, and sarcopenia
| Outcome | Setting | Women (vs men) | Fit, aged (vs younger) | Sarcopenia/reduced skeletal muscle (vs no sarcopenia) |
| Safety | Palliative chemotherapy | Increased gastrointestinal and hematological toxicities (5-FU, oxaliplatin, irinotecan) | Increased diarrhea and neutropenia (5-FU, oxaliplatin, irinotecan) | Increased neurological, gastrointestinal and hematological toxicities |
| Increased nausea (trifluridine/tipiracil) | No difference (trifluridine/tipiracil) | Frequent DLT (5-FU, oxaliplatin) | ||
| No difference (anti-VEGF) | Increased thrombocytopenia (bevacizumab) | Frequent DLT (regorafenib) | ||
| No different toxicity (anti-EGFR) | No different toxicity (fruquintinib) | |||
| Increased fatigue, hypertension, skin toxicity, and anorexia (regorafenib) | Increased diarrhea, frequent body weight loss (aflibercept) | |||
| No different toxicity (T-Dxd) | No different toxicity (regorafenib) | |||
| Severer irAEs (ICIs) | ||||
| Chemoradiotherapy | Frequent interruption and discontinuation | Frequent dose reduction | Probable increased cystitis and thrombocytopenia | |
| Increased diarrhea, perianal dermatitis, and hematological toxicities | No different toxicity | |||
| Adjuvant chemotherapy | Frequent dose reduction (5-FU, oxaliplatin). Decreased completion rate (oxaliplatin) | No different toxicity (5-FU) | Decreased completion rate (oxaliplatin) | |
| Probable increased toxicity (oxaliplatin) | Frequent DLT (oxaliplatin) | |||
| Efficacy | Palliative chemotherapy | Comparable PFS and OS (5-FU, oxaliplatin) | Comparable RR and OS (5-FU) | Poorer PFS and OS (5-FU, oxaliplatin) |
| Comparable PFS and OS (ICIs) | Comparable RR and undermined survival benefit (oxaliplatin, irinotecan) | |||
| Comparable PFS and OS (trifluridine/tipiracil) | ||||
| Comparable PFS and undermined survival benefit (bevacizumab) | ||||
| Comparable OS (ramucirumab, aflibercept, fruquintinib) | ||||
| Comparable RR and PFS (anti-EGFR) | ||||
| Comparable RR and PFS (T-Dxd) | ||||
| No survival benefit (pembrolizumab) | ||||
| Comparable PFS (nivolumab + ipilimumab) | ||||
| Chemoradiotherapy | Comparable tumor regression and pathological response | Comparable tumor regression and pathological response | Undetermined impact on response | |
| Adjuvant chemotherapy | Better DFS, RFS, and OS (5-FU, oxaliplatin) | Comparable survivals (5-FU) | Undetermined survival benefit (5-FU, oxaliplatin) | |
| Undetermined survival benefit (oxaliplatin) |
- Citation: Nozawa H, Murono K, Emoto S, Ishihara S. Three S’s (sex, seniors, and sarcopenia) matter during chemotherapy for colorectal cancer. World J Clin Oncol 2026; 17(11): 127405
- URL: https://www.wjgnet.com/2218-4333/full/v17/i11/127405.htm
- DOI: https://dx.doi.org/10.5306/wjco.127405